Quantitative phosphoproteomics analysis of ERBB3/ERBB4 signaling

PLoS ONE

Volumn 11, Issue 1, 2016, Pages

  Wandinger, Sebastian K ^a   Lahortiga, Idoya ^b,c   Jacobs, Kris ^b,c   Klammer, Martin ^a   Jordan, Nicole ^a   Elschenbroich, Sarah ^a   Parade, Marc ^d   Jacoby, Edgar ^d   Linders, Joannes T M ^d   Brehmer, Dirk ^d   Cools, Jan ^b,c   Daub, Henrik ^a  

^a Evotec München GmbH Dept of Bioinformatics   (Germany)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; MITOGEN ACTIVATED PROTEIN KINASE; NEU DIFFERENTIATION FACTOR; PHOSPHOPROTEOME; PROTEIN KINASE B; PROTEOME; UNCLASSIFIED DRUG; ERBB3 PROTEIN, MOUSE; ERBB4 PROTEIN, MOUSE; NRG1 PROTEIN, MOUSE; PHOSPHOPROTEIN; PROTEIN BINDING;

ANIMAL CELL; ARTICLE; BIOINFORMATICS; CELL PROLIFERATION; CONTROLLED STUDY; ISOTOPE LABELING; MASS SPECTROMETRY; NONHUMAN; PHOSPHOPROTEOMICS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEOMICS; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; WORKFLOW; AMINO ACID SEQUENCE; ANIMAL; B LYMPHOCYTE; CELL LINE; CYTOLOGY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETIC ENGINEERING; GENETICS; HUMAN; METABOLISM; MOLECULAR GENETICS; MOUSE; PHOSPHORYLATION; PROTEIN ANALYSIS;

AMINO ACID SEQUENCE; ANIMALS; B-LYMPHOCYTES; CELL LINE; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORKS; GENETIC ENGINEERING; HUMANS; MICE; MOLECULAR SEQUENCE DATA; NEUREGULIN-1; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; PROTEOME; RECEPTOR, ERBB-3; RECEPTOR, ERBB-4; SIGNAL TRANSDUCTION;

EID: 84954357714     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0146100     Document Type: Article

References (63)

1. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005; 5: 341-54. doi: 10.1038/nrc1609 PMID: 15864276
2. Roskoski R Jr. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res. 2014; 79: 34-74. doi: 10.1016/j.phrs.2013.11.002 PMID: 24269963
3. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001; 2: 127-37. doi: 10.1038/35052073 PMID: 11252954
4. Shi F, Telesco SE, Liu Y, Radhakrishnan R, Lemmon MA. ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. Proc Natl Acad Sci U S A. 2010; 107: 7692-7. doi: 10.1073/pnas.1002753107 PMID: 20351256
5. van der Horst EH, Weber I, Ullrich A. Tyrosine phosphorylation of PYK2 mediates heregulin-induced glioma invasion: novel heregulin/HER3-stimulated signaling pathway in glioma. Int J Cancer. 2005; 113: 689-98. doi: 10.1002/ijc.20643 PMID: 15499613
6. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer. 2009; 9: 463-75. doi: 10.1038/nrc2656 PMID: 19536107
7. Jura N, Shan Y, Cao X, Shaw DE, Kuriyan J. Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3. Proc Natl Acad Sci U S A. 2009; 106: 21608-13. doi: 10.1073/pnas.0912101106 PMID: 20007378
8. Mok TS. Personalized medicine in lung cancer: what we need to know. Nat Rev Clin Oncol. 2011; 8: 661-8. doi: 10.1038/nrclinonc.2011.126 PMID: 21862980
9. Jaiswal BS, Kljavin NM, Stawiski EW, Chan E, Parikh C, Durinck S, et al. Oncogenic ERBB3 mutations in human cancers. Cancer Cell. 2013; 23: 603-17. doi: 10.1016/j.ccr.2013.04.012 PMID: 23680147
10. Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature. 2007; 445: 437-41. doi: 10.1038/nature05474 PMID: 17206155
11. Wheeler DL, Huang S, Kruser TJ, Nechrebecki MM, Armstrong EA, Benavente S, et al. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene. 2008; 27: 3944-56. doi: 10.1038/onc.2008.19 PMID: 18297114
12. Fattore L, Marra E, Pisanu ME, Noto A, de Vitis C, Belleudi F, et al. Activation of an early feedback survival loop involving phospho-ErbB3 is a general response of melanoma cells to RAF/MEK inhibition and is abrogated by anti-ErbB3 antibodies. J Transl Med. 2013; 11: 180. doi: 10.1186/1479-5876-11-180 PMID: 23890105
13. Blobel CP, Carpenter G, Freeman M. The role of protease activity in ErbB biology. Exp Cell Res. 2009; 315: 671-82. doi: 10.1016/j.yexcr.2008.10.011 PMID: 19013149
14. Prickett TD, Agrawal NS, Wei X, Yates KE, Lin JC, Wunderlich JR, et al. Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat Genetics. 2009; 41: 1127-32. doi: 10.1038/ng.438 PMID: 19718025
15. Nielsen TO, Poulsen SS, Journe F, Ghanem G, Sorensen BS. HER4 and its cytoplasmic isoforms are associated with progression-free survival of malignant melanoma. Melanoma Res. 2014; 24: 88-91. doi: 10.1097/CMR.0000000000000040 PMID: 24366194
16. Sartor CI, Zhou H, Kozlowska E, Guttridge K, Kawata E, Caskey L, et al. Her4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells. Mol Cell Biol. 2001; 21: 4265-75. doi: 10.1128/MCB.21.13.4265-4275.2001 PMID: 11390655
17. Naresh A, Thor AD, Edgerton SM, Torkko KC, Kumar R, Jones FE. The HER4/4ICD estrogen receptor coactivator and BH3-only protein is an effector of tamoxifen-induced apoptosis. Cancer Res. 2008; 68: 6387-95. doi: 10.1158/0008-5472.CAN-08-0538 PMID: 18676864
18. Naresh A, Long W, Vidal GA, Wimley WC, Marrero L, Sartor CI, et al. The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells. Cancer Res. 2006; 66: 6412-20. doi: 10.1158/0008-5472.CAN-05-2368 PMID: 16778220
19. Mohd Nafi SN, Generali D, Kramer-Marek G, Gijsen M, Strina C, Cappelletti M, et al. Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer. Oncotarget. 2014; 5: 5934-49. PMID: 25153719
20. Hollmen M, Maatta JA, Bald L, Sliwkowski MX, Elenius K. Suppression of breast cancer cell growth by a monoclonal antibody targeting cleavable ErbB4 isoforms. Oncogene. 2009; 28: 1309-19. doi: 10.1038/onc.2008.481 PMID: 19151766
21. Tang CK, Concepcion XZ, Milan M, Gong X, Montgomery E, Lippman ME. Ribozyme-mediated downregulation of ErbB-4 in estrogen receptor-positive breast cancer cells inhibits proliferation both in vitro and in vivo. Cancer Res. 1999; 59: 5315-22. PMID: 10537315
22. Veikkolainen V, Vaparanta K, Halkilahti K, Iljin K, Sundvall M, Elenius K. Function of ERBB4 is determined by alternative splicing. Cell Cycle. 2011; 10: 2647-57. PMID: 21811097
23. De Keersmaecker K, Graux C, Odero MD, Mentens N, Somers R, Maertens J, et al. Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32). Blood. 2005; 105: 4849-52. doi: 10.1182/blood-2004-12-4897 PMID: 15713800
24. Oppermann FS, Klammer M, Bobe C, Cox J, Schaab C, Tebbe A, et al. Comparison of SILAC and mTRAQ quantification for phosphoproteomics on a quadrupole orbitrap mass spectrometer. J Proteome Res. 2013; 12: 4089-100. doi: 10.1021/pr400417g PMID: 23898821
25. Kang UB, Yeom J, Kim H, Lee C. Quantitative analysis of mTRAQ-labeled proteome using full MS scans. J Proteome Res. 2010; 9: 3750-8. doi: 10.1021/pr9011014 PMID: 20465265
26. Wang Y, Yang F, Gritsenko MA, Clauss T, Liu T, Shen Y, et al. Reversed-phase chromatography with multiple fraction concatenation strategy for proteome profiling of human MCF10A cells. Proteomics. 2011; 11: 2019-26. doi: 10.1002/pmic.201000722 PMID: 21500348
27. Mertins P, Qiao JW, Patel J, Udeshi ND, Clauser KR, Mani DR, et al. Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods. 2013; 10: 634-7. doi: 10.1038/nmeth.2518 PMID: 23749302
28. Olsen JV, de Godoy LM, Li G, Macek B, Mortensen P, Pesch R, et al. Parts per million mass accuracy on an Orbitrap mass spectrometer via lock mass injection into a C-trap. Mol Cell Proteomics. 2005; 4: 2010-21. PMID: 16249172
29. Schroeder MJ, Shabanowitz J, Schwartz JC, Hunt DF, Coon JJ. A neutral loss activation method for improved phosphopeptide sequence analysis by quadrupole ion trap mass spectrometry. Anal Chem. 2004; 76: 3590-8. PMID: 15228329
30. Cox J, Neuhauser N, Michalski A, Scheltema RA, Olsen JV, Mann M. Andromeda: a peptide search engine integrated into the MaxQuant environment. J Proteome Res. 2011; 10: 1794-805. doi: 10.1021/pr101065j PMID: 21254760
31. Vizcaino JA, Deutsch EW, Wang R, Csordas A, Reisinger F, Rios D, et al. ProteomeXchange provides globally coordinated proteomics data submission and dissemination. Nat Biotechnol. 2014; 32: 223-6. doi: 10.1038/nbt.2839 PMID: 24727771
32. Olsen JV, Blagoev B, Gnad F, Macek B, Kumar C, Mortensen P, et al. Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell. 2006; 127: 635-48. PMID: 17081983
33. Klammer M, Dybowski JN, Hoffmann D, Schaab C. Identification of significant features by the Global Mean Rank test. PLoS One. 2014; 9: e104504. doi: 10.1371/journal.pone.0104504 PMID: 25119995
34. Al-Shahrour F, Arbiza L, Dopazo H, Huerta-Cepas J, Minguez P, Montaner D, et al. From genes to functional classes in the study of biological systems. BMC Bioinformatics. 2007; 8: 114. doi: 10.1186/1471-2105-8-114 PMID: 17407596
35. Klammer M, Godl K, Tebbe A, Schaab C. Identifying differentially regulated subnetworks from phosphoproteomic data. BMC Bioinformatics. 2010; 11: 351. doi: 10.1186/1471-2105-11-351 PMID: 20584295
36. Cline MS, Smoot M, Cerami E, Kuchinsky A, Landys N, Workman C, et al. Integration of biological networks and gene expression data using Cytoscape. Nat Protoc. 2007; 2: 2366-82. PMID: 17947979
37. Warmuth M, Kim S, Gu XJ, Xia G, Adrian F. Ba/F3 cells and their use in kinase drug discovery. Curr Opin Oncol. 2007; 19: 55-60. doi: 10.1097/CCO.0b013e328011a25f PMID: 17133113
38. Zhou W, Carpenter G. Heregulin-dependent trafficking and cleavage of ErbB-4. J Biol Chem. 2000; 275: 34737-43. doi: 10.1074/jbc.M003756200 PMID: 10944525
39. Szklarczyk D, Franceschini A, Kuhn M, Simonovic M, Roth A, Minguez P, et al. The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res. 2011; 39: D561-8. doi: 10.1093/nar/gkq973 PMID: 21045058
40. Miller ML, Jensen LJ, Diella F, Jorgensen C, Tinti M, Li L, et al. Linear motif atlas for phosphorylation dependent signaling. Sci Signal. 2008; 1: ra2. doi: 10.1126/scisignal.1159433 PMID: 18765831
41. Sasaoka T, Ishiki M, Wada T, Hori H, Hirai H, Haruta T, et al. Tyrosine phosphorylation-dependent and -independent role of Shc in the regulation of IGF-1-induced mitogenesis and glycogen synthesis. Endocrinology. 2001; 142: 5226-35. doi: 10.1210/endo.142.12.8543 PMID: 11713219
42. Lazer G, Pe'er L, Farago M, Machida K, Mayer BJ, Katzav S. Tyrosine residues at the carboxyl terminus of Vav1 play an important role in regulation of its biological activity. J Biol Chem. 2010; 285: 23075-85. doi: 10.1074/jbc.M109.094508 PMID: 20457609
43. Dougherty MK, Muller J, Ritt DA, Zhou M, Zhou XZ, Copeland TD, et al. Regulation of Raf-1 by direct feedback phosphorylation. Mol Cell. 2005; 17: 215-24. doi: 10.1016/j.molcel.2004.11.055 PMID: 15664191
44. Ritt DA, Monson DM, Specht SI, Morrison DK. Impact of feedback phosphorylation and Raf heterodimerization on normal and mutant B-Raf signaling. Mol Cell Biol. 2010; 30: 806-19. doi: 10.1128/MCB. 00569-09 PMID: 19933846
45. Yeh E, Cunningham M, Arnold H, Chasse D, Monteith T, Ivaldi G, et al. A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol. 2004; 6: 308-18. doi: 10.1038/ncb1110 PMID: 15048125
46. Yang X, Liu L, Sternberg D, Tang L, Galinsky I, DeAngelo D, et al. The FLT3 internal tandem duplication mutation prevents apoptosis in interleukin-3-deprived BaF3 cells due to protein kinase A and ribosomal S6 kinase 1-mediated BAD phosphorylation at serine 112. Cancer Res. 2005; 65: 7338-47. doi: 10.1158/0008-5472.CAN-04-2263 PMID: 16103085
47. Takahashi E, Abe J, Gallis B, Aebersold R, Spring DJ, Krebs EG, et al. p90(RSK) is a serum-stimulated Na+/H+ exchanger isoform-1 kinase. Regulatory phosphorylation of serine 703 of Na+/H+ exchanger isoform-1. J Biol Chem. 1999; 274: 20206-14. PMID: 10400637
48. Abe Y, Yoon SO, Kubota K, Mendoza MC, Gygi SP, Blenis J. p90 ribosomal S6 kinase and p70 ribosomal S6 kinase link phosphorylation of the eukaryotic chaperonin containing TCP-1 to growth factor, insulin, and nutrient signaling. J Biol Chem. 2009; 284: 14939-48. doi: 10.1074/jbc.M900097200 PMID: 19332537
49. Roux PP, Ballif BA, Anjum R, Gygi SP, Blenis J. Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc Natl Acad Sci U S A. 2004; 101: 13489-94. doi: 10.1073/pnas.0405659101 PMID: 15342917
50. Zhu QS, Rosenblatt K, Huang KL, Lahat G, Brobey R, Bolshakov S, et al. Vimentin is a novel AKT1 target mediating motility and invasion. Oncogene. 2011; 30: 457-70. doi: 10.1038/onc.2010.421 PMID: 20856200
51. Yoshizaki T, Imamura T, Babendure JL, Lu JC, Sonoda N, Olefsky JM. Myosin 5a is an insulin-stimulated Akt2 (protein kinase Bbeta) substrate modulating GLUT4 vesicle translocation. Mol Cell Biol. 2007; 27: 5172-83. doi: 10.1128/MCB.02298-06 PMID: 17515613
52. Hayakawa J, Ohmichi M, Kurachi H, Kanda Y, Hisamoto K, Nishio Y, et al. Inhibition of BAD phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin. Cancer Res. 2000; 60: 5988-94. PMID: 11085518
53. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 1999; 96: 857-68. S0092-8674(00)80595-4 PMID: 10102273
54. Wang L, Harris TE, Lawrence JC Jr. Regulation of proline-rich Akt substrate of 40 kDa (PRAS40) function by mammalian target of rapamycin complex 1 (mTORC1)-mediated phosphorylation. J Biol Chem. 2008; 283: 15619-27. doi: 10.1074/jbc.M800723200 PMID: 18372248
55. Hashimoto M, Sagara Y, Langford D, Everall IP, Mallory M, Everson A, et al. Fibroblast growth factor 1 regulates signaling via the glycogen synthase kinase-3beta pathway. Implications for neuroprotection. J Biol Chem. 2002; 277: 32985-91. doi: 10.1074/jbc.M202803200 PMID: 12095987
56. Park HS, Kim MS, Huh SH, Park J, Chung J, Kang SS, et al. Akt (protein kinase B) negatively regulates SEK1 by means of protein phosphorylation. J Biol Chem. 2002; 277: 2573-8. doi: 10.1074/jbc. M110299200 PMID: 11707464
57. Bauer DE, Hatzivassiliou G, Zhao F, Andreadis C, Thompson CB. ATP citrate lyase is an important component of cell growth and transformation. Oncogene. 2005; 24: 6314-22. PMID: 16007201
58. Weiss FU, Wallasch C, Campiglio M, Issing W, Ullrich A. Distinct characteristics of heregulin signals mediated by HER3 or HER4. J Cell Physiol. 1997; 173: 187-95. PMID: 9365520
59. Davies S, Holmes A, Lomo L, Steinkamp MP, Kang H, Muller CY, et al. High incidence of ErbB3, ErbB4, and MET expression in ovarian cancer. Int J Gynecol Pathol. 2014; 33: 402-10. doi: 10.1097/PGP.0000000000000081 PMID: 24901400
60. Paatero I, Lassus H, Junttila TT, Kaskinen M, Butzow R, Elenius K. CYT-1 isoform of ErbB4 is an independent prognostic factor in serous ovarian cancer and selectively promotes ovarian cancer cell growth in vitro. Gynecol Oncol. 2013; 129: 179-87. doi: 10.1016/j.ygyno.2012.12.044 PMID: 23313737
61. Sheng Q, Liu X, Fleming E, Yuan K, Piao H, Chen J, et al. An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell. 2010; 17: 298-310. doi: 10.1016/j. ccr.2009.12.047 PMID: 20227043
62. Hegde GV, de la Cruz CC, Chiu C, Alag N, Schaefer G, Crocker L, et al. Blocking NRG1 and other ligand-mediated Her4 signaling enhances the magnitude and duration of the chemotherapeutic response of non-small cell lung cancer. Sci Transl Med. 2013; 5: 171ra18. doi: 10.1126/scitranslmed. 3004438 PMID: 23390248
63. Ubersax JA, Ferrell JE Jr. Mechanisms of specificity in protein phosphorylation. Nat Rev Mol Cell Biol. 2007; 8: 530-41. PMID: 17585314